Abstracts Archive - Page 858 of 2607 - ACR Meeting Abstracts

Abstract Number: 0324 • ACR Convergence 2020
Comparative Responsiveness of Outcome Measures in Psoriatic Arthritis: Preparation for Pragmatic Trials
Courtney Stull¹, Soumya Reddy², M. Elaine Husni³, Jose Scher⁴, Ethan Craig¹, Jessica Walsh⁵ and Alexis Ogdie¹, ¹University of Pennsylvania, Philadelphia, PA, ²NYU School of Medicine, New York, NY, ³Cleveland Clinic, Cleveland, OH, ⁴NYU School of Medicine, New York City, ⁵University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition; this presents a challenge in how to best measure disease activity for all patients. While several outcome…
Abstract Number: 0325 • ACR Convergence 2020
The Impact of PsA Disease Control Status on Patient Treatment Satisfaction: Real-world Survey in US and Europe
Ana-Maria Orbai¹, Elizabeth Holdsworth², Thomas Baker³, Chloe Middleton-Dalby², May Shawi³, Nicola Booth², James Piercy² and Steven Peterson⁴, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Adelphi Real World, Bollington, United Kingdom, ³Janssen Global Services, LLC, Raritan, NJ, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: Patient satisfaction associated with disease control status among PsA patients has not been extensively studied in a real-world setting. The objective of this study…
Abstract Number: 0326 • ACR Convergence 2020
Flares Among Patients with Psoriatic Arthritis (PsA) – Frequency and Impact on Patient Outcomes: Real-world Survey in the US and Europe
Ana-Maria Orbai¹, William Tillett², Suzann Grieb³, James Piercy⁴, Steven Peterson⁵, Elizabeth Holdsworth⁴, Sophie Meakin⁴, Soumya Chakravarty⁶, Nicola Booth⁴ and Laure Gossec⁷, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ³John Hopkins University School of Medicine, Baltimore, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Sorbonne University, INSERM; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Flares in PsA, presenting as periods of acute disease activity, are thought to negatively impact patients’ lives. This has not been extensively studied in…
Abstract Number: 0327 • ACR Convergence 2020
Skin Involvement in Psoriatic Arthritis (PsA) – The Incremental Impact of Psoriasis on Quality of Life, Disability and Work Productivity: Real-world Survey in US and Europe
Jessica Walsh¹, Alexis Ogdie², Kaleb Michaud³, Steven Peterson⁴, Elizabeth Holdsworth⁵, Sophie Meakin⁵, Soumya Chakravarty⁶, Nicola Booth⁵, Agata Schubert⁷, James Piercy⁵ and Laure Gossec⁸, ¹University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ³University of Nebraska Medical Center, Omaha, NE, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen-Cilag, Janssen-Cilag, Poland, ⁸Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France
Background/Purpose: The degree of joint and skin involvement varies across patients with PsA. Differences in patient outcomes with active joint only vs. joint plus skin…
Abstract Number: 0328 • ACR Convergence 2020
Healthcare Utilization and Costs Among Patients with Psoriatic Arthritis and Psoriasis in the United States – a Retrospective Study of Claims Data from 2009 to 2020
Joseph Merola¹, Reginald Villacorta², Natalie Dennis³, Soumya Chakravarty⁴, Laura Mesana⁵, Iris Lin², Maud Pacou³, Thomas Baker⁶, Yiting Wang⁷ and Steven Peterson⁸, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Janssen Immunology Global Commercial Strategy Organization, Horsham, ³Amaris, Paris, France, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁵Amaris, New York, ⁶Janssen Global Services, LLC, Raritan, NJ, ⁷Janssen R&D, LLC, Titusville, ⁸Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: The costs of psoriasis and psoriatic arthritis (PsA) are substantial for both patients and the United States healthcare system. This study compared healthcare resource…
Abstract Number: 0329 • ACR Convergence 2020
Healthcare Utilization and Costs Associated with Functional Status in Patients with Psoriatic Arthritis
Alexis Ogdie¹, Mark Hwang², Phani Veeranki³, Alexandria Portelli³, Steven Sison³, Jason Shafrin³, Sofia Pedro⁴, Peter Hur⁵, Nina Kim⁶ and Kaleb Michaud⁷, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³PRECISIONheor, Los Angeles, ⁴FORWARD-The National Data Bank for Rheumatic Diseases, Wichita, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶The University of Texas at Austin; Baylor Scott and White Health, Austin, TX, ⁷FORWARD-The National Data Bank for Rheumatic Diseases; University of Nebraska Medical Center, Wichita
Background/Purpose: The Health Assessment Questionnaire Disability Index (HAQ-DI) has been validated and widely used in psoriatic arthritis (PsA) clinical trials for the assessment of patient…
Abstract Number: 0330 • ACR Convergence 2020
Musculoskeletal Surgery in Psoriatic Arthritis: Prevalence and Risk Factors
Timothy Kwok¹, Mitchell Sutton², Daniel Pereira², Vinod Chandran³ and Dafna Gladman³, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Prognosis Studies in the Rheumatic Diseases, Krembil Research Institute, Toronto Western Hospital, University Health Network, Toronto, Canada, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Despite optimal medical therapy, joint space disease and skeletal damage persists in a subset of patients with PsA, many of whom requiring musculoskeletal (MSK)…
Abstract Number: 0331 • ACR Convergence 2020
Work Absenteeism and Disability Associated with Psoriatic Arthritis and Psoriasis in the United States – A Retrospective Study of Claims Data from 2009 to 2020
Ana-Maria Orbai¹, Soumya Reddy², Steven Peterson³, Natalie Dennis⁴, Reginald Villacorta⁵, Laura Mesana⁶, Soumya Chakravarty⁷, Maud Pacou⁴, Iris Lin⁵, Thomas Baker⁸, Yiting Wang⁹ and Jessica Walsh¹⁰, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²NYU School of Medicine, New York City, ³Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁴Amaris, Paris, France, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, ⁶Amaris, New York, ⁷Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁸Janssen Global Services, LLC, Raritan, NJ, ⁹Janssen R&D, LLC, Titusville, ¹⁰University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT
Background/Purpose: Absenteeism and work disability substantially contribute to the economic burden of psoriasis and psoriatic arthritis (PsA). This study compared work absenteeism and short-term disability…
Abstract Number: 0332 • ACR Convergence 2020
Guselkumab Improved Work Productivity and Daily Activity in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Jeffrey R Curtis¹, Iain McInnes², Proton Rahman³, William Tillett⁴, Philip Mease⁵, Alexa Kollmeier⁶, Elizabeth Hsia⁷, Bei Zhou⁸, Prasheen Agarwal⁸, Steven Peterson⁹ and Chenglong Han⁸, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ⁵Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁶Janssen Research & Development, LLC, La Jolla, CA, ⁷Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁸Janssen Research & Development, LLC, Spring House, PA, ⁹Janssen Immunology Global Commercial Strategy Organization, Horsham, PA
Background/Purpose: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific MAb Guselkumab (GUS) in PsA patients, who experience impaired physical function, resulting in…
Abstract Number: 0333 • ACR Convergence 2020
Comparative Effectiveness of Secukinumab, Adalimumab and Other Tumor Necrosis Factor Inhibitors Used with or Without Methotrexate in the Treatment of Psoriatic Arthritis
Denis Choquette¹, Loïc Choquette Sauvageau², Louis Bessette³, Isabelle Ferdinand², Boulos Haraoui⁴, Frédéric Massicotte², Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard², Diane Sauvageau², Édith Villeneuve² and Louis Coupal², ¹Institut de Rhumatologie de Montréal, Montreal, Canada, ²Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ³Laval University, Quebec, Canada, ⁴Rheumatology Institute of Montréal, Montreal, Canada
Background/Purpose: The treatment of psoriatic arthritis has evolved with the addition of agents targeting a different cytokine, Il-17 introduced in 2016. It has proven to…
Abstract Number: 0334 • ACR Convergence 2020
Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis
Philip Mease¹, Iain McInnes², Kiefer Eaton³, Steven Peterson⁴, Tim Disher⁵, Soumya Chakravarty⁶, Chetan Karyekar⁷, Sandhya Nair⁸, Wolf-Henning Boehncke⁹ and Christopher Ritchlin¹⁰, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ³EVERSANA, Burlington, Canada, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵EVERSANA, Sydney, Australia, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Global Services, LLC, Horsham, PA, ⁸Janssen Pharmaceutica NV, Beerse, ⁹Geneva University Hospitals, Geneva, Switzerland, ¹⁰Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: The efficacy of the interleukin (IL)-23 subunit p19 inhibitor guselkumab (GUS) for psoriatic arthritis (PsA) has recently been demonstrated in two Phase 3 trials…
Abstract Number: 0335 • ACR Convergence 2020
Interleukin-17 Blockade Leads to Shifts from Stage-based Towards Response-based Disease Clusters- Comparative Data from Very Early and Established Psoriatic Arthritis
Eleni Kampylafka¹, Koray Tascilar², Veronika Lerchen³, Chistina Linz³, Maria Sokolova³, Ana Zekovic³, Arnd Kleyer², David Simon², Juergen Rech², Michael Sticherling¹, Georg Schett⁴ and Axel Hueber³, ¹Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander- University Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Germany, ⁴Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany
Background/Purpose: Limited information exists about the very early forms of psoriatic arthritis (PsA). In particular, differences and responsiveness of patient-reported outcomes (PROs) in very early…
Abstract Number: 0336 • ACR Convergence 2020
Anxiety and Depression in Psoriatic Arthritis (PsA) – Prevalence and Impact on Patient Reported Outcomes: Real-World Survey in the US and Europe
Laure Gossec¹, Jessica Walsh², Kaleb Michaud³, Elizabeth Holdsworth⁴, Steven Peterson⁵, Sophie Meakin⁴, Nicola Booth⁴, Soumya Chakravarty⁶, James Piercy⁴ and Alexis Ogdie⁷, ¹Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³University of Nebraska Medical Center, Omaha, NE, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Anxiety and depression are comorbidities among PsA patients. The impact of anxiety and depression on outcomes in PsA patients has not been characterized in…
Abstract Number: 0337 • ACR Convergence 2020
Similar Impact of Psoriatic Arthritis and Rheumatoid Arthritis on Objective and Subjective Parameters of Hand Function
Anna-Maria Liphardt¹, Eva Manger², Sonja Liehr², Lisa Bieniek², Arnd Kleyer³, David Simon³, Koray Tascilar³, Michael Sticherling⁴, Juergen Rech³, Georg Schett⁵ and Axel Hueber⁶, ¹Friedrich-Alexander-University Erlangen-Nuremberg, Internal Medicine 3 - Rheumatology & Immunology, University Hospital Erlangen, Erlangen, Bayern, Germany, ²Departement of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nuremberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Bayern, Germany, ⁴Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ⁵Friedrich-Alexander-Universität Erlangen- Nuremberg, Erlangen, Germany, ⁶Sozialstiftung Bamberg, Sektion Rheumatologie, Bamberg, Germany
Background/Purpose: To compare the impact of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) on objective and subjective parameters of hand function.Methods: Hand function was assessed…
Abstract Number: 0338 • ACR Convergence 2020
Increased Risk of Lymphoproliferative Disorders in Psoriatic Arthritis
Eugenia Chen¹ and Maida Wong², ¹Department of Medicine, University of California Irvine, Orange, CA, ²Division of Rheumatology, Department of Medicine, VA Long Beach Healthcare System, Long Beach, CA
Background/Purpose: Psoriatic arthritis (PsA) is a systemic inflammatory disease that involves musculoskeletal and skin manifestations. Such autoimmune disease has been associated with increased lymphoproliferative disease…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].